1613. Global 2018 Surveillance of Eravacycline Against Gram-negative Pathogens, Including Multi-drug Resistant Isolates

BACKGROUND: Eravacycline (ERV) is a fully-synthetic, fluorocycline antibacterial approved by the FDA and EMA for treatment of complicated intra-abdominal infections (cIAI) in patients ≥18 years of age. The purpose of this study was to describe the in vitro activity of ERV against Gram-negative patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Lijfrock, Virgil, Morgan, Steven, Hwang, Sara, Efimova, Ekaterina, Lawrence, Kenneth, Hawser, Stephen, Morrissey, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777381/
http://dx.doi.org/10.1093/ofid/ofaa439.1793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777381/
http://dx.doi.org/10.1093/ofid/ofaa439.1793

Ejemplares similares